Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
vindesine/illamående
Länken sparas på Urklipp
Sida 1 från 82 resultat
Vindesine, etoposide (VP-16), and prednisolone (VEP) in relapsed patients with grade II non-Hodgkin's lymphoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Vindesine, etoposide (VePesid), and prednisolone (VEP) have been evaluated as a second-line combination regimen in 20 patients with grade II non-Hodgkin's lymphoma (NHL) who relapsed during or after first-line intensive therapy. The overall response rate was 40% (20% complete, of 9 to 13+ months'
[Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Seventeen patients with recurrent or refractory non-Hodgkin's lymphoma were treated with EMVP (Etoposide 75 mg/m2 i.v. d 1-5, Methotrexate 100mg/m2 i.v. d 1, Vindesine 3 mg/body i.v. d 1, Prednisolone 60 mg/m2 p.o. d 1-5), repeating every 3 weeks. Six complete responses (35%) and five partial
A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
192 evaluable patients with advanced inoperable non-small-cell lung cancer were treated with either mitomycin-C/ifosfamide (A), mitomycin-C/vindesine (B), or cisplatin/etoposide (C) in a prospective randomized trial. The response rates for each treatment arm were 30.0% (A), 22.7% (B), and 25% (C),
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
We treated 27 patients with regionally advanced non-small-cell lung cancer (NSCLC) with two cycles of neoadjuvant chemotherapy with etoposide, vindesine, and cisplatin. Twenty-three patients were evaluable for response; 13 had a partial response while ten patients had stable disease or disease
A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
We conducted a randomized trial testing etoposide (120 mg/m2 d1-3) + vindesine (3 mg/m2 d1) with or without cisplatin (60 mg/m2 d1) in patients with SCLC. A total of 8 courses were given at 3-week intervals. 221 patients were registered and 201, 95 in the CEV arm and 106 in the EV arm, were eligible
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Thirty-two patients with advanced Hodgkin's lymphoma resistant to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were treated with a salvage chemotherapy regimen consisting of lomustine, etoposide, vindesine, and
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
The modest improvement in median survival of advanced non-small-cell lung cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical benefit for the patient is at least as important an end-point as objective response rate (ORR) or survival. Clinical
Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Seventy-one patients with epidermoid carcinoma of the esophagus were treated with a three-drug combination of cisplatin, vindesine, and bleomycin. Forty-five patients had local-regional tumor and received chemotherapy prior to surgery or radiation therapy. Twenty-six patients with extensive disease
Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Forty-six patients with inoperable cancer and leukemia in relapse were given vindesine (VDS) either by iv bolus weekly at doses ranging from 2.0 to 5.5 mg/m2 or by 24-hour continuous infusion weekly at doses ranging from 1.0 to 7.0 mg/m2 of estimated body surface area. VDS was well-tolerated by
Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Thirteen-cis retinoic acid (RA) has been shown to have growth-inhibitory and differentiative activity on non-small cell lung cancer (NSCLC) cells in vitro. This promoted the rationale for combining RA with three active drugs, cisplatin (CDDP) vindesine (VDS) and mitomycin-c (MMC) in the
[Combination chemotherapy of primary adenocarcinoma of the lung using adriamycin, ACNU, and vindesine].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Since July 1980, thirty patients with inoperable adenocarcinoma of the lung have been treated with ANV. Induction chemotherapy (Adriamycin 35 mg/m2 i.v. days 1 and 22, ACNU 2 mg/kg i.v. day 1, vindesine 2 mg/m2 i.v. days 1, and 22) was given for 2 courses (or 1 course) at 3-week intervals.
Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A total of 36 patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of 5-day continuous i.v. infusion of cisplatin (25 mg/m2 daily), bolus infusion of vindesine (3 mg/m2) on days 1 and 8, and s.c. injection of recombinant human granulocyte-colony-stimulating
[Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
53 patients with advanced and measurable cancerr were treated with vindesine in doses of 3 mg/m2 (pretreated) and 4 mg/m2 (non pretreated) i.v. once weekly. 48 patients are evaluable for response: of 14 patients with squamous cell carcinoma of the lung, 1 partial remission (PR), 1 minor response
A randomized trial comparing vindesine and cisplatinum to vindesine and methotrexate in advanced non small cell lung carcinoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Combination chemotherapy using vindesine and cisplatinum has been reported to be active in non-small cell lung carcinoma (NSCLC). In an attempt to reduce the potential neurotoxicity of this combination, and to assess the role of cisplatinum, a randomized trial has compared vindesine and cisplatinum
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer. A total of 295 patients was randomly allocated to treatment with vindesine 3 mg/m2 combined with either epirubicin 40 mg/m2 or
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
